Within this context, our study focused on the genetic variations of the KYN pathway to provide possible markers (1) to predict depressive side effects of IFN-α therapy in treated patients and (2) for the screening for susceptibility of inflammation-induced depression in the general population. Here, IFNA17 is linked to depressive symptom measurement.